



Kala BIO, Inc. (KALA)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001479419

Kala BIO, Inc. KALA; healthcare		
Grade	None 6 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025	
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	under \$12.5M assets total assets \$9.5M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	dilution, short runway, late filer, thin data, degenerate inputs; fo	
Inputs computable	6 of 14	
Graded from	filings received through Apr 15, 2026 177 days before the rescan; latest periodic filing 10-Q received Aug 19, 2026	
Last close	\$0.30 2026-10-08; market equity \$5.7M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Apr 15, 2026

In this Annual Report on Form 10-K, unless the context otherwise requires, references to "we," "us," "our," "our company," "KALA," "KALA BIO" and "Company" refer to KALA BIO, Inc. and its subsidiaries. We are a biopharmaceutical company in transition, evaluating the development of a dedicated, on-premises artificial intelligence (AI) infrastructure platform for the biotechnology industry. Our current focus is leveraging our mesenchymal stem cell secretome ("MSC-S") platform to test development of a scalable AI platform-as-a-service business to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 94.0						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		15.4%	(6.6%)	94.0	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 76.9						
Twelve-month failure probability		0.51%	0.07%	83.8	248	2026-06-30
Altman Z double-prime		(258.66)	(0.31)	98.8	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		3.81x	2.96x	48.0	839	2025-12-31
Growth and financing, sleeve percentile 98.9						
Revenue growth, three-year compound		not computable	10.0%			current value must be positive and the base must exceed \$100,000
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 3
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(52.2%)	2.1%	98.3	704	2025-12-31
Net share issuance, one year		14,305.4%	2.5%	99.5	634	2026-04-10

Warnings

6 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 14305.4%
Short runway	cash runway is 0.1 months
Late filer	found 3 NT 10-K/Q filings in the last eight quarters
Thin data	6 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor
Fortress balance sheet	cash minus debt is 27,192,000 USD; Altman Z is not used

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(99.1%)	8.0%	0

Distance from 52-week high	(99.6%)	(31.4%)	0
EBIT to enterprise value	(120.7%)	(1.5%)	5
Free cash flow yield	(1,639.7%)	(1.0%)	0
Book value to price	1.58	0.28	94
Sales to price	0.00	0.31	0
Composite equity issuance, five years	666.6%	20.3%	99
Relative strength against the sector, log excess return	(4.95)	(0.14)	0

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$229,000
Operating cash flow, four quarters	-\$19.9M
Months of runway	0.1
Days since last periodic filing	51 (10-Q received Aug 19, 2026)
Median daily dollar volume, 63 sessions	\$90,415

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$27.0M	2025-12-31	2026-04-15	10-K	0001104659-26-043782
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$32.0M	2025-12-31	2026-04-15	10-K	0001104659-26-043782
3	assets	us-gaap:Assets	\$9.5M	2025-12-31	2026-04-15	10-K	0001104659-26-043782
4	assets	us-gaap:Assets	\$55.5M	2024-12-31	2026-04-15	10-K	0001104659-26-043782
5	current assets	us-gaap:AssetsCurrent	\$9.5M	2025-12-31	2026-04-15	10-K	0001104659-26-043782
6	current liabilities	us-gaap:LiabilitiesCurrent	\$2.5M	2025-12-31	2026-04-15	10-K	0001104659-26-043782
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$694.9M	2025-12-31	2026-04-15	10-K	0001104659-26-043782
8	operating income	us-gaap:OperatingIncomeLoss	-\$39.2M	2025-12-31	2026-04-15	10-K	0001104659-26-043782
9	book equity	us-gaap:StockholdersEquity	\$7.0M	2025-12-31	2026-04-15	10-K	0001104659-26-043782
10	liabilities	us-gaap:Liabilities	\$2.5M	2025-12-31	2026-04-15	10-K	0001104659-26-043782
11	total debt	us-gaap:LongTermDebt	\$43.3M	2022-12-31	2023-03-03	10-K	0001558370-23-002746
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$70.5M	2022-12-31	2024-03-29	10-K	0001558370-24-004326
13	operating income	us-gaap:OperatingIncomeLoss	-\$81.7M	2022-12-31	2024-03-29	10-K	0001558370-24-004326
14	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$537,000	2022-12-31	2024-03-29	10-K	0001558370-24-004326
15	operating income	us-gaap:OperatingIncomeLoss	-\$39.7M	2023-12-31	2025-03-31	10-K	0001558370-25-004081
16	interest expense	us-gaap:InterestExpense	\$5.8M	2023-12-31	2024-03-29	10-K	0001558370-24-004326
17	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$0	2025-12-31	2026-04-15	10-K	0001104659-26-043782
18	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$0	2024-12-31	2026-04-15	10-K	0001104659-26-043782
19	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$0	2023-12-31	2025-03-31	10-K	0001558370-25-004081
20	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$3.9M	2022-12-31	2024-03-29	10-K	0001558370-24-004326
21	assets	us-gaap:Assets	\$55.9M	2023-12-31	2025-03-31	10-K	0001558370-25-004081
22	assets	us-gaap:Assets	\$86.8M	2022-12-31	2024-03-29	10-K	0001558370-24-004326
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	929,491,578	2026-04-10	2026-04-15	10-K	0001104659-26-043782
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	6,452,398	2025-03-28	2025-03-31	10-K	0001558370-25-004081